Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis

Podobne zapisy

• Peginterferon beta-1a reduces disability worsening in relapsing–remitting multiple sclerosis: 2-year results from ADVANCE
  od: Scott D. Newsome, i wsp.
  Wydane: (2017-01-01)
• Peginterferon beta-1a reduces disability worsening in relapsing–remitting multiple sclerosis: 2-year results from ADVANCE
  od: Newsome, Scott D., i wsp.
  Wydane: (2016)
• Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis
  od: Newsome, Scott D., i wsp.
  Wydane: (2016)
• Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis
  od: Arnold, Douglas L, i wsp.
  Wydane: (2014)
• Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial
  od: Arnold, Douglas L., i wsp.
  Wydane: (2017)